Compare Realty Income Corp (O) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Realty Income Corp trades at $54.05 (market cap $50.48B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Realty Income Corp's market cap, and Realty Income Corp pays a 6.11% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 127 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| O | VRTX | |
|---|---|---|
Market Cap | $50.48B | $128.16B |
Volume | 6,493,749 | 806,603 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $557.96 |
52-Week Low | $53.35 | $407.37 |
Typical Hold Time | 127 Days | 120 Days |
Enterprise Value | $81.11B | $122.29B |
Dividend Yield | 6.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $53.35, down 1.66% amid bearish technical signals and recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though rising bond yields pressure valuations. Analyst consensus remains cautiously optimistic with a $64.80 price target despite three consecutive quarterly EPS misses.
The stock faces near-term headwinds from technical weakness and interest rate sensitivity, but long-term investors may find value in the 6%+ dividend yield and A-rated balance sheet. Key risks include persistent earnings underperformance and debt levels approaching 40% of assets, requiring careful monitoring of Q3 2026 results due November 2.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
